18F-FLT PET during radiotherapy or chemoradiotherapy in head and neck squamous cell carcinoma is an early predictor of outcome

Journal of Nuclear Medicine

Volumn 54, Issue 4, 2013, Pages 532-540

  Hoeben, Bianca A W ^a   Troost, Esther G C ^a   Span, Paul N ^a   Van Herpen, Carla M L ^a   Bussink, Johan ^a   Oyen, Wim J G ^a   Kaanders, Johannes H A M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

18F fluorothymidine PET; head and neck cancer; early response monitoring

Indexed keywords

3' FLUOROTHYMIDINE F 18; CISPLATIN; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; 3' FLUOROTHYMIDINE; DIAGNOSTIC AGENT;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CORRELATION ANALYSIS; DIAGNOSTIC IMAGING; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMAGE DISPLAY; MALE; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; RADIOLOGICAL PARAMETERS; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR VOLUME; CLINICAL TRIAL; HEAD AND NECK TUMOR; METABOLISM; MIDDLE AGED; SCINTISCANNING; SQUAMOUS CELL CARCINOMA; TIME; TRANSPORT AT THE CELLULAR LEVEL;

ADULT; AGED; BIOLOGICAL TRANSPORT; CARCINOMA, SQUAMOUS CELL; DIDEOXYNUCLEOSIDES; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; TIME FACTORS; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 84875763897     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.105999     Document Type: Article

References (40)

1. 18F-FDG PET in oncology. J Nucl Med. 2008;49:480-508.
2. Bussink J, Kaanders JH, van der Graaf WT, Oyen WJ. PET-CT for radiotherapy treatment planning and response monitoring in solid tumors. Nat Rev Clin Oncol. 2011;8:233-242.
3. Strauss LG. Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients. Eur J Nucl Med. 1996;23:1409-1415.
4. Troost EG, Schinagl DA, Bussink J, et al. Innovations in radiotherapy planning of head and neck cancers: role of PET. J Nucl Med. 2010;51:66-76.
5. 18F]fluorothymidinepositron emission tomography for noninvasive assessment of proliferation in pulmonary nodules. Cancer Res. 2002;62:3331-3334.
6. Kim JJ, Tannock IF. Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat Rev Cancer. 2005;5:516-525.
7. Fu KK, Pajak TF, Trotti A, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys. 2000;48:7-16.
8. Overgaard J, Hansen HS, Specht L, et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet. 2003;362:933-940.
9. Blanchard P, Baujat B, Holostenco V, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site. Radiother Oncol. 2011;100:33-40.
10. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous- cell carcinoma of the head and neck. N Engl J Med. 2006;354:567-578.
11. Rütten H, Pop LA, Janssens GO, et al. Long-term outcome and morbidity after treatment with accelerated radiotherapy and weekly cisplatin for locally advanced head-and-neck cancer: results of a multidisciplinary late morbidity clinic. Int J Radiat Oncol Biol Phys. 2011;81:923-929.
12. Bussink J, van Herpen CM, Kaanders JH, Oyen WJ. PET-CT for response assessment and treatment adaptation in head and neck cancer. Lancet Oncol. 2010;11:661-669.
13. Shields AF, Grierson JR, Kozawa SM, Zheng M. Development of labeled thymidine analogs for imaging tumor proliferation. Nucl Med Biol. 1996;23: 17-22.
14. Shields AF, Grierson JR, Dohmen BM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 1998;4:1334-1336.
15. Rasey JS, Grierson JR, Wiens LW, Kolb PD, Schwartz JL. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med. 2002;43:1210-1217.
16. Bading JR, Shields AF. Imaging of cell proliferation: status and prospects. J Nucl Med. 2008;49(suppl 2):64S-80S.
17. 18F] fluorothymidine PET to monitor early responses to radiation therapy in murine SCCVII tumors. Eur J Nucl Med Mol Imaging. 2006;33:412-419.
18. 18F-FLT PET/CT for early response monitoring and dose escalation in oropharyngeal tumors. J Nucl Med. 2010;51:866-874.
19. 18F-FLT) in head and neck cancer patients before and early after initiation of chemoradiation therapy. J Nucl Med. 2009;50:1028-1035.
20. Sobin L, Wittekind C. 2002 UICC: TNM Classification of Malignant Tumours. 6th ed. New York, NY: Wiley-Liss; 2002:19-42.
21. Vogel WV, Wensing BM, van Dalen JA, Krabbe PF, van den Hoogen FJ, Oyen WJ. Optimised PET reconstruction of the head and neck area: improved diagnostic accuracy. Eur J Nucl Med Mol Imaging. 2005;32:1276-1282.
22. Daisne JF, Sibomana M, Bol A, Doumont T, Lonneux M, Gregoire V. Tri-dimensional automatic segmentation of PET volumes based on measured source-to-background ratios: influence of reconstruction algorithms. Radiother Oncol. 2003;69:247-250.
23. 18F-FLT positron emission tomography/computed tomography imaging for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2009;75:1098-1104.
24. 18F]fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging. 2007;34:1339-1347.
25. 18F]FLT: an imaging biomarker of tumour proliferation for assessment of tumour response to treatment. Eur J Cancer. 2012;48:416-424.
26. 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib. Clin Cancer Res. 2011;17: 3304-3315.
27. Pio BS, Park CK, Pietras R, et al. Usefulness of 39-[F-18]fluoro-39- deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Mol Imaging Biol. 2006;8:36-42.
28. 18F-fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab. J Nucl Med. 2012;53: 29-36.
29. 18F]39-deoxy- 39-fluorothymidine for prediction of response to neoadjuvant treatment in patients with rectal cancer. Eur J Nucl Med Mol Imaging. 2007;34:878-883.
30. 18F-FLT PET during radiotherapy of esophageal squamous cell carcinoma: a pilot clinical study. J Nucl Med. 2010;51:528-534.
31. 18F]fluorothymidine positron emission tomography before and 7 days after gefitinib treatment predicts response in patients with advanced adenocarcinoma of the lung. Clin Cancer Res. 2008;14:7423-7429.
32. 18F]fluorothymidine positron emission tomography. J Clin Oncol. 2011;29:1701-1708.
33. 18F]fluoro-2-deoxy-D-glucose. Int J Radiat Oncol Biol Phys. 2004;59:1295-1300.
34. 18F-FDG PET for primary treatment strategy in patients with squamous cell carcinoma of the oropharynx. J Nucl Med. 2007;48:752-757.
35. Schwartz DL, Rajendran J, Yueh B, et al. FDG-PET prediction of head and neck squamous cell cancer outcomes. Arch Otolaryngol Head Neck Surg. 2004;130: 1361-1367.
36. Murphy JD, La TH, Chu K, et al. Postradiation metabolic tumor volume predicts outcome in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2011;80:514-521.
37. Isles MG, McConkey C, Mehanna HM. A systematic review and meta-analysis of the role of positron emission tomography in the follow up of head and neck squamous cell carcinoma following radiotherapy or chemoradiotherapy. Clin Otolaryngol. 2008;33:210-222.
38. Hentschel M, Appold S, Schreiber A, et al. Early FDG PET at 10 or 20 Gy under chemoradiotherapy is prognostic for locoregional control and overall survival in patients with head and neck cancer. Eur J Nucl Med Mol Imaging. 2011;38: 1203-1211.
39. 18F-FDG PET-CT be used as prognostic factors for the clinical outcome of patients with locally advanced head and neck cancer treated with radio-chemotherapy? Radiother Oncol. 2012;103:63-68.
40. 18F-FDG PET. J Nucl Med. 2004;45:226-231.